ABVC BIOPHARMA, INC.

Tickers
ABVC, ECOC
Headquarters
Not recorded
SEC CIK
0001173313
Website
Not recorded

Closing prices

Latest close, 1.04

Closing prices for ABVC249 stored closes for ABVC from 3 Nov 2025 to 29 Oct 2026. Lowest 0.71 on 26 Aug 2026, highest 2.99 on 12 Nov 2025, latest 1.04 on 29 Oct 2026.Close0.001.002.003.003 Nov 20251 May 202629 Oct 2026
249 stored closes, oldest first. End of day, not intraday.

Drugs

No drugs from this company are tracked yet.

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue296,000 USD 1 Jan 2025 to 31 Dec 2025 FY202510-K for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)−736,934 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense22,707 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses779,526 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents31,944 USD At 30 Jun 2026 FY2026 Q210-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities62,420 USD At 30 Jun 2026 FY2026 Q210-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities7,131,155 USD At 30 Jun 2026 FY2026 Q210-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity10,287,183 USD At 30 Jun 2026 FY2026 Q210-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)26,654,365 shares At 10 Aug 2026 FY2026 Q210-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Jan 2025 to 31 Dec 2025 FY2025296,000 USD10-K filed 3 Mar 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2025 Q3795,950 USD10-Q filed 3 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 FY2025509,589 USD10-K filed 3 Mar 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Sep 2024 FY2025 Q3389,276 USD10-Q/A filed 3 Mar 2026 on sec.gov (opens in a new tab)Filed
1 Apr 2024 to 30 Jun 2024 FY2025 Q2117,142 USD10-Q filed 13 Aug 2025 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Mar 2024 FY2025 Q11,205 USD10-Q filed 30 Apr 2025 on sec.gov (opens in a new tab)Filed
1 Jan 2023 to 31 Dec 2023 FY2024152,430 USD10-K filed 15 Apr 2025 on sec.gov (opens in a new tab)Filed
1 Jul 2023 to 30 Sep 2023 FY2024 Q315,884 USD10-Q filed 14 Nov 2024 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read

SEC filings

SEC filings from ABVC BIOPHARMA, INC., newest first
FormFiledWhat it coversDocument
DEF 14AEvent 28 Oct 2026 Proxy statement (DEF 14A) View Proxy statement (DEF 14A) filed 29 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-104509 (opens in a new tab)
8-K Current report (8-K)
  • Entry into a material definitive agreement (Item 1.01)
  • Completion of acquisition or disposition of assets (Item 2.01)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 27 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-094152 (opens in a new tab)
424B4 Form 424B4 View Form 424B4 filed 17 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-090779 (opens in a new tab)
424B4 Form 424B4 View Form 424B4 filed 17 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-090778 (opens in a new tab)
424B4 Form 424B4 View Form 424B4 filed 17 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-090777 (opens in a new tab)
424B4 Form 424B4 View Form 424B4 filed 17 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-090775 (opens in a new tab)
10-QEvent 30 Jun 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 12 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-088348 (opens in a new tab)
8-K/AEvent 3 Aug 2026 Amended current report (8-K/A)
  • Other events (Item 8.01)
View Amended current report (8-K/A) filed 12 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-088165 (opens in a new tab)
8-KEvent 3 Aug 2026 Current report (8-K)
  • Other events (Item 8.01)
View Current report (8-K) filed 4 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-084846 (opens in a new tab)
8-K Current report (8-K)
  • Change of certifying accountant (Item 4.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 2 Jul 2026 on sec.gov (opens in a new tab)Filing index for 0001213900-26-074949 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
None in this period

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.